» Articles » PMID: 3053167

The Promoter of Alzheimer's Disease Amyloid A4 Precursor Gene

Overview
Journal EMBO J
Date 1988 Sep 1
PMID 3053167
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

The promoter of the gene for the human precursor of Alzheimer's disease A4 amyloid protein (PAD gene) resembles promoters of housekeeping genes. It lacks a typical TATA box and shows a high GC content of 72% in a DNA region that confers promoter activity to a reporter gene in an in vivo assay. Transcription initiates at multiple sites. Sequences homologous to the consensus binding sites of transcription factor AP-1 and the heat shock control element binding protein were found upstream of the RNA start sites. Six copies of a 9-bp-long GC-rich element are located between positions -200 and -100. A protein--DNA interaction could be mapped to this element. The 3.8 kb of the 5' region of the PAD gene include two Alu-type repetitive sequences. These findings suggest that four mechanisms may participate in the regulation of the PAD gene and could be of relevance for the progression of amyloid deposition in Alzheimer's disease.

Citing Articles

Production of Amyloid-β in the Aβ-Protein-Precursor Proteolytic Pathway Is Discontinued or Severely Suppressed in Alzheimer's Disease-Affected Neurons: Contesting the 'Obvious'.

Volloch V, Rits-Volloch S Genes (Basel). 2025; 16(1.

PMID: 39858593 PMC: 11764795. DOI: 10.3390/genes16010046.


Quintessential Synergy: Concurrent Transient Administration of Integrated Stress Response Inhibitors and BACE1 and/or BACE2 Activators as the Optimal Therapeutic Strategy for Alzheimer's Disease.

Volloch V, Rits-Volloch S Int J Mol Sci. 2024; 25(18).

PMID: 39337400 PMC: 11432332. DOI: 10.3390/ijms25189913.


ACH2.0/E, the Consolidated Theory of Conventional and Unconventional Alzheimer's Disease: Origins, Progression, and Therapeutic Strategies.

Volloch V, Rits-Volloch S Int J Mol Sci. 2024; 25(11).

PMID: 38892224 PMC: 11172602. DOI: 10.3390/ijms25116036.


On the Inadequacy of the Current Transgenic Animal Models of Alzheimer's Disease: The Path Forward.

Volloch V, Rits-Volloch S Int J Mol Sci. 2024; 25(5).

PMID: 38474228 PMC: 10932000. DOI: 10.3390/ijms25052981.


Tolfenamic Acid Derivatives: A New Class of Transcriptional Modulators with Potential Therapeutic Applications for Alzheimer's Disease and Related Disorders.

Hill J, Shalaby K, Bihaqi S, Alansi B, Barlock B, Parang K Int J Mol Sci. 2023; 24(20).

PMID: 37894896 PMC: 10607430. DOI: 10.3390/ijms242015216.


References
1.
BENDITT E, Eriksen N . Chemical classes of amyloid substance. Am J Pathol. 1971; 65(1):231-52. PMC: 2047520. View

2.
Shivers B, Hilbich C, Multhaup G, Salbaum M, Beyreuther K, Seeburg P . Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact. EMBO J. 1988; 7(5):1365-70. PMC: 458385. DOI: 10.1002/j.1460-2075.1988.tb02952.x. View

3.
SANGER F, Nicklen S, Coulson A . DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977; 74(12):5463-7. PMC: 431765. DOI: 10.1073/pnas.74.12.5463. View

4.
Razin A, Riggs A . DNA methylation and gene function. Science. 1980; 210(4470):604-10. DOI: 10.1126/science.6254144. View

5.
Dignam J, Lebovitz R, Roeder R . Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983; 11(5):1475-89. PMC: 325809. DOI: 10.1093/nar/11.5.1475. View